| 1. |
|
|
| 2. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 3. |
|
|
| 4. |
- Rabih, A. A. S., et al.
(författare)
-
MEMS-Based Acetone Vapor Sensor for Non-Invasive Screening of Diabetes
- 2018
-
Ingår i: IEEE Sensors Journal. - 1530-437X .- 1558-1748. ; 18:23, s. 9486-9500
-
Tidskriftsartikel (refereegranskat)abstract
- Acetone vapor sensing is important for environmental monitoring and non-invasive screening of diabetes mellitus (DM). Inhaling higher than 176 parts per million (ppm) acetone concentrations affects the respiratory system, while acetone in exhaled breath correlates with blood glucose and exhaling more than 1.8 ppm indicates the person is in danger of DM. DM is currently diagnosed invasively by measuring glucose level in blood, which is painful, and therefore inconvenient. This paper reports MEMS sensor device functionalized with blend of Chitosan/Polyethylene glycol polymers for acetone vapor sensing for possible non-invasive screening of diabetes. The sensor was experimentally tested using synthetic acetone vapor, and found to give linear response for 0.05-5 ppm acetone in air, with a sensitivity of 21 mV/ppm, good repeatability, response, and reversibility. Cross-sensitivity for 2-propanol and methanol was examined, where the responses of the sensor to 1 ppm concentration in air of these two analytes were found to be 24% and 33%, respectively, less compared to its response to the same concentration of acetone.
|
|
| 5. |
- Rabih, A. A. S., et al.
(författare)
-
MetalMUMPs resonator for acetone vapor sensing
- 2017
-
Ingår i: Proceedings of the 2017 IEEE regional symposium on micro and nanoelectronics (RSM). - : IEEE. - 9781509040292 ; , s. 5-9
-
Konferensbidrag (refereegranskat)abstract
- Acetone vapor monitoring is essential in workplace for human health and safety, where exposure to acetone concentration more than 176 parts per million (ppm) can cause damage to eyes, liver, kidneys and central nervous system. In addition, acetone in exhaled breath is known to be good biomarker for non-invasive screening of diabetes. The most common used acetone vapor sensors are based on metal oxide semiconductor sensors, which work at higher temperatures, and hence consume more power. This paper reports MetalMUMPs device for acetone vapor sensing for environmental monitoring. The device is based on electrothermal actuation and capacitive sensing using differential capacitance measurement technique. MS3110 universal capacitive readout circuit was used to readout the small change of the static capacitance when the device is actuated using 0.71 Vrms with a driving frequency range of 0.5 kHz-8 kHz. The output signal of the circuit is given as a voltage and it can be directly related to the capacitance change. The output voltage change was found to increase linearly with increasing the acetone vapor concentration from 100 ppm to 500 ppm with a concentration sensitivity of 0.65 mV/ppm.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
